Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Triamcinolone · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Triamcinolone | DRUG | - |
Inclusion Criteria: * Subjects will be male or female children ages 2-5 years with a history of at least 1 year of perennial allergic rhinitis (PAR) with or without seasonal allergic rhinitis (SAR) characterized by nasal stuffiness, nasal discharge, sneezing, nasal itching, and total eye symptoms, ...
Triamcinolone is a small molecule developed by Sanofi for the treatment of perennial allergic rhinitis, a year-round allergic nasal condition. It is being studied in a Phase 3 clinical program, including a completed trial in children ages 2 to 5 years with this indication.
Triamcinolone targets NR3C1, the glucocorticoid receptor, and acts as an agonist at this receptor. By binding and activating NR3C1, it produces glucocorticoid effects relevant to controlling allergic inflammation in perennial allergic rhinitis.
Sanofi is the developer of Triamcinolone, traded under the ticker SNY. The company is advancing the small molecule through clinical development for perennial allergic rhinitis.
Triamcinolone is in Phase 3 development for perennial allergic rhinitis. It is an investigational therapy and is not approved based on the development information available. The Phase 3 program includes one completed trial with 460 enrolled participants.
Triamcinolone has been evaluated in the Phase 3 trial NCT00132925, titled an efficacy and safety evaluation of Nasacort AQ in children ages 2 to 5 years with perennial allergic rhinitis. The trial enrolled 460 participants in the United States and is completed.
Nasacort AQ is a nasal spray formulation of Triamcinolone. The Phase 3 trial NCT00132925 evaluated Nasacort AQ in children ages 2 to 5 years with perennial allergic rhinitis, so references to Nasacort AQ in this program describe the same active drug.